{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-24-000084","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.884420+00:00","generated_at":"2026-06-02T09:53:43.142572+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sera Prognostics Q1 net loss narrows to $8.1M; net revenue nil after adjustments","bullets":["Net revenue nil after periodic review of accounting estimates for older tests; gross revenue $39K vs $100K YoY.","Net loss $8.1M, improved 24% from $10.6M loss in Q1 2023.","Operating expenses $9.1M, down 20% YoY; SG&A $5.4M (-26%), R&D $3.7M (-10%).","Shipped first ambient whole blood collection kits to reduce COGS and expand access.","Submitted PRIME study interim analysis manuscript for peer-reviewed publication."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-24-000084","json":"https://secwatch.observer/filing/0001534969-24-000084.json","markdown":"https://secwatch.observer/filing/0001534969-24-000084.md","text":"https://secwatch.observer/filing/0001534969-24-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496924000084/0001534969-24-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496924000084/sera-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:53:43.142572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d74f9109e0134dbb369220ab0a13e5e8c86ca4ad","claim":"SERA PROGNOSTICS, INC. reported first quarter ended March 31, 2024 results: revenue nil, net income $8.1 million loss.","evidence_excerpt":"First quarter 2024 revenue before adjustments was $39,000 compared to $100,000 for the same period of 2023, but net revenue was nil after our periodic review of accounting estimates for older tests.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534969/000153496924000084/0001534969-24-000084-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"nil"},{"label":"Net income","value":"$8.1 million loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}